The U.S. Food and Drug Administration approved Johnson & Johnson's ketamine-based nasal spray Spravato to treat adults with major depressive disorder, the company said on Tuesday. The approval paves the way for use of Spravato in patients whose disease has stopped responding to at least two oral anti-depressants.

A one-time nasal spray has been approved by the Food and Drug Administration as a standalone treatment for depression.

The Food and Drug Administration (FDA) has approved Spravato, a nasal spray developed by Johnson & Johnson, as a standalone treatment for adults with major depressive disorder who have not responded to at least two other antidepressants.

"Treatment-resistant depression can be very complicated, especially for patients who do not respond to oral antidepressants or cannot tolerate them. For too long, health care providers have had few options to offer patients much-needed symptom improvement,

In today's Health Alert, the FDA has approved the first stand-alone nasal spray to treat drug-resistant depression.

The company said that the nasal spray is a ketamine-derived drug, first approved in 2019, to be used in combination with antid

The FDA says esketamine, an antidepressant derived from the anesthetic and party drug ketamine, can now be prescribed on its own. It was approved in 2019 to treat severe depression.

A new nasal drug has been approved to treat depression. The drug Spravato  is a nasal spray made by Johnson and Johnson.

Celebrities like Chrissy Teigen and Matthew Perry have been open about using ketamine for their mental health – here's what they've said

The FDA approved Johnson & Johnson's Spravato, a ketamine-based nasal spray, to treat adults with major depressive disorder who have not responded to at least two oral antidepressants. This approval addresses the need for new options for treatment-resistant depression,

The U.S. Food and Drug Administration ( FDA) has approved the use of a nasal spray as a standalone treatment for major depressive disorder, offering a new option for those struggling with treatment-resistant depression.